| Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients. | |
| | |
MedLine Citation:
|
PMID: 9512874 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effects of treatment with low-dose 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pravastatin on the changes of chemical composition and in vitro oxidative susceptibility of low-density lipoprotein (LDL) were studied in 20 type Ila hyperlipidemic patients with a plasma total cholesterol level > 240 mg/dL at the end of a diet control period for 3 months using the American Heart Association recommended step I diet. Treatment with pravastatin in a dose of 5 mg twice daily for 4 weeks resulted in lowering plasma total and LDL cholesterol levels by 17.0% and 22.9%, respectively. There was no further decline in plasma lipid thereafter. Chemical composition analysis showed that LDL particles did not contain significantly less cholesterol and thiobarbituric acid reactive substances (TBARS) until the end of 8 weeks (130.6 +/- 17.8 vs. 106.6 +/- 37.1 mg/mg protein, P < 0.05 and 0.16 +/- 0.06 vs. 0.08 +/- 0.02 nmol/mg protein, P < 0.005, respectively). Vitamin E, phospholipid, and triglyceride contents remained at the same levels throughout the study. In terms of oxidative kinetics, lag time and time to maximal diene concentration were not prolonged during the treatment period for 12 weeks, while total diene concentration and reaction rate were not significantly reduced until 8 weeks of treatment. Plasma enzyme activity of glutathione reductase and peroxidase, as well as the whole blood level of reduced and oxidized glutathione, remained similar during the study. In conclusion, pravastatin, at the low dose of 5 mg twice daily, produced a significant decline in plasma lipid levels to a steady-state range by 4 weeks; however, 8-weeks treatment is necessary to reduce the cholesterol and TBARS content, as well as to attenuate the oxidative susceptibility of LDL. These effects are not related to the antioxidant glutathione. |
| | |
Authors:
|
M F Chen; H C Hsu; Y T Lee |
Related Documents
:
|
17519084 - Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in pat... 10924734 - Ldl physical properties, lipoprotein and lp(a) levels in acromegalic patients. effects ... 7661884 - Autoantibodies against malondialdehyde-modified ldl are elevated in subjects with an ld... 12009424 - Association of plasma phospholipid transfer protein activity with idl and buoyant ldl: ... 23628364 - Plasma concentrations of pgfm and uterine and ovarian responses in early lactation dair... 1287264 - Acute effects of alcohol on cognitive function and central nervous system assessed by a... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy Volume: 11 ISSN: 0920-3206 ISO Abbreviation: Cardiovasc Drugs Ther Publication Date: 1997 Dec |
Date Detail:
|
Created Date: 1998-04-30 Completed Date: 1998-04-30 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8712220 Medline TA: Cardiovasc Drugs Ther Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 787-93 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine (Cardiology), National Taiwan University Medical Center, Taipei, Taiwan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antilipemic Agents / pharmacology* Female Glutathione / metabolism Humans Hypercholesterolemia / metabolism* Kinetics Lipids / blood Lipoproteins, LDL / blood, metabolism* Male Oxidation-Reduction Phenotype Pravastatin / pharmacology* Thiobarbituric Acid Reactive Substances Vitamin E / blood |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Lipids; 0/Lipoproteins, LDL; 0/Thiobarbituric Acid Reactive Substances; 1406-18-4/Vitamin E; 70-18-8/Glutathione; 81093-37-0/Pravastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A new platelet-activating factor antagonist (CV-6209) in preservation of heart and lung for transpla...
Next Document: Effect of hypotensive drugs on the circadian blood pressure pattern in essential hypertension: a com...